In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly owned pipeline, including Descartes-08, Cartesian’s clinical-stage lead product candidate being evaluated in patients with myasthenia gravis and other autoimmune diseases. For more information about the company and updates, please visit https://www.cartesiantherapeutics.com/ or follow us on LinkedIn @Cartesian-Therapeutics.
| Website | http://www.selectabio.com |
| Revenue | $7.3 million |
| Employees | 14 (14 on RocketReach) |
| Address | 65 Grove Street, Watertown, Massachusetts 02472, US |
| Industry | Biotechnology Research |
| Keywords | Rna Therapeutics, Gene Therapy, Targeted Therapy, Cell Therapy, Immunotherapy, Autoimmune Diseases, Biotechnology, Therapeutic Antibodies, Immune System, Pharmaceutical, Drug Development, Precision Medicine, Drug Delivery, Biologics, Genetic Engineering, Clinical Trials, Rare Diseases, Molecular Biology, Oncology |
| Competitors | Pfizer, AstraZeneca, Sanofi, Regeneron, GSK, CureVac, Novavax, Moderna Therapeutics, Merck AH, Vaxart, Inc. +51 more (view full list) |
Looking for a particular Selecta Biosciences employee's phone or email?
Selecta Biosciences Questions
The Selecta Biosciences annual revenue was $7.3 million in 2026.
John Alvino is the Senior Director, CMC-RA of Selecta Biosciences.
14 people are employed at Selecta Biosciences.
Selecta Biosciences is based in Watertown, Massachusetts.
Top Selecta Biosciences Employees
-
John Alvino
Senior Director, CMC-RA at Selecta Biosciences
Watertown, MA, US55+
Related Companies
